DnB Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$36.1M Buy
285,591
+12,484
+5% +$1.64M 0.1% 138
2026
Q1
$38.1M Buy
273,107
+18,664
+7% +$2.61M 0.14% 118
2025
Q4
$31.2M Buy
254,443
+9,326
+4% +$1.13M 0.11% 131
2025
Q3
$27.2M Sell
245,117
-44,223
-15% -$5.03M 0.1% 150
2025
Q2
$32.1M Buy
289,340
+61,277
+27% +$6.52M 0.13% 117
2025
Q1
$25.6M Sell
228,063
-75,040
-25% -$7.74M 0.12% 137
2024
Q4
$28M Buy
303,103
+14,626
+5% +$1.32M 0.12% 137
2024
Q3
$24.2M Sell
288,477
-2,326
-0.8% -$177K 0.11% 148
2024
Q2
$20M Buy
290,803
+93,165
+47% +$6.22M 0.1% 156
2024
Q1
$14.5M Sell
197,638
-53,988
-21% -$4.15M 0.08% 190
2023
Q4
$20.4M Sell
251,626
-58,703
-19% -$4.57M 0.11% 161
2023
Q3
$23.3M Buy
310,329
+2,417
+0.8% +$186K 0.14% 125
2023
Q2
$23.7M Sell
307,912
-7,725
-2% -$616K 0.14% 125
2023
Q1
$26.2M Sell
315,637
-6,567
-2% -$544K 0.17% 118
2022
Q4
$27.7M Sell
322,204
-5,010
-2% -$397K 0.2% 112
2022
Q3
$20.2M Sell
327,214
-57,724
-15% -$3.64M 0.16% 133
2022
Q2
$23.8M Sell
384,938
-20,854
-5% -$1.29M 0.17% 121
2022
Q1
$24.1M Buy
405,792
+58,670
+17% +$3.75M 0.14% 132
2021
Q4
$25.2M Buy
347,122
+30,308
+10% +$2.09M 0.15% 131
2021
Q3
$22.1M Sell
316,814
-651
-0.2% -$45.7K 0.14% 135
2021
Q2
$21.9M Buy
317,465
+7,116
+2% +$475K 0.14% 128
2021
Q1
$20.1M Sell
310,349
-1,223,144
-80% -$78.9M 0.15% 121
2020
Q4
$89.3M Sell
1,533,493
-288,155
-16% -$17.4M 0.78% 22
2020
Q3
$115M Buy
1,821,648
+1,481,374
+435% +$103M 1.22% 16
2020
Q2
$26.2M Buy
340,274
+59,282
+21% +$4.54M 0.31% 60
2020
Q1
$21M Buy
280,992
+108,091
+63% +$7.47M 0.31% 61
2019
Q4
$11.2M Sell
172,901
-55,705
-24% -$3.63M 0.11% 143
2019
Q3
$14.5M Sell
228,606
-87,820
-28% -$5.74M 0.16% 106
2019
Q2
$21.4M Buy
316,426
+25,719
+9% +$1.69M 0.25% 78
2019
Q1
$18.9M Sell
290,707
-30,086
-9% -$2M 0.22% 84
2018
Q4
$20.1M Buy
320,793
+33,981
+12% +$2.38M 0.26% 78
2018
Q3
$22.1M Buy
286,812
+130,260
+83% +$9.84M 0.25% 77
2018
Q2
$11.1M Buy
156,552
+6,600
+4% +$466K 0.13% 119
2018
Q1
$11.3M Buy
149,952
+13,100
+10% +$1.04M 0.14% 120
2017
Q4
$9.8M Buy
136,852
+2,370
+2% +$180K 0.12% 128
2017
Q3
$10.9M Sell
134,482
-115,900
-46% -$8.86M 0.14% 110
2017
Q2
$17.7M Buy
250,382
+36,400
+17% +$2.42M 0.26% 77
2017
Q1
$14.5M Sell
213,982
-15,300
-7% -$1.08M 0.23% 86
2016
Q4
$16.4M Buy
229,282
+3,100
+1% +$230K 0.3% 73
2016
Q3
$17.9M Buy
226,182
+31,900
+16% +$2.59M 0.35% 68
2016
Q2
$16.2M Sell
194,282
-37,000
-16% -$3.28M 0.34% 71
2016
Q1
$21.2M Buy
231,282
+115,300
+99% +$10.4M 0.44% 56
2015
Q4
$11.7M Buy
115,982
+4,200
+4% +$437K 0.25% 82
2015
Q3
$11M Hold
111,782
0.27% 81
2015
Q2
$13.1M Sell
111,782
-15,100
-12% -$1.65M 0.29% 74
2015
Q1
$12.5M Buy
126,882
+46,600
+58% +$4.73M 0.28% 78
2014
Q4
$7.57M Sell
80,282
-4,400
-5% -$455K 0.17% 113
2014
Q3
$9.01M Buy
84,682
+5,600
+7% +$548K 0.2% 92
2014
Q2
$6.56M Buy
+79,082
New +$6.16M 0.14% 114
2013
Q4
$5.34M Sell
71,082
-6,900
-9% -$480K 0.13% 120
2013
Q3
$4.9M Sell
77,982
-21,518
-22% -$1.29M 0.13% 99
2013
Q2
$5.1M Buy
+99,500
New +$5.19M 0.15% 89

Other funds holding GILD

DnB Asset Management's GILD Position: Q2 2026 in Review

DnB Asset Management increased its Gilead Sciences (GILD) stake by 4.6% in Q2 2026, buying an estimated $1.64M and bringing the position to 285,591 shares worth $36.1M. The position accounts for 0.1% of the portfolio, ranked #138.

DnB Asset Management first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $115M in Q3 2020. 1,640 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • DnB Asset Management held 285,591 shares of Gilead Sciences worth $36.1M as of Q2 2026.
  • DnB Asset Management bought 12,484 Gilead Sciences shares in Q2 2026, an estimated $1.64M.
  • Gilead Sciences made up 0.1% of DnB Asset Management's portfolio in Q2 2026, its #138 holding.
  • DnB Asset Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • DnB Asset Management's Gilead Sciences position peaked at $115M in Q3 2020.
  • 1,640 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.